On the evening of February 7, Aohua Endoscopy (Shanghai stock code: 688212) announced that the two shareholders planned to reduce their holdings by no more than 4,037,600 shares due to their own capital needs, and the total reduction ratio did not exceed 3% of the company's total share capital.

According to the announcement, the shareholders who threw out the shareholding reduction plan are Suzhou Junlian Xinkang Venture Capital Partnership (Limited Partnership) (hereinafter referred to as "Junlian Xinkang") and Gao Shen Co., Ltd. (hereinafter referred to as "Gao Shen"). The two constitute a concerted action relationship, holding a total of 6,619,200 shares of Aohua Endoscopy, accounting for 4.92% of the company's total share capital.

It is worth noting that from May to August 2024, Junlian Xinkang and Gao Shen have reduced their holdings of 2.0217 million shares of Aohua Endoscopy, with a reduction price of 41.24 yuan/share - 53.07 yuan/share. Based on this calculation, the total cash out of the two is about 83.38 million yuan - 107 million yuan.

In addition, Shenzhen Business Daily has noticed that since 2024, many shareholders of Aohua Endoscopy have thrown out their shareholding reduction plans. Among them, the shareholder Appalachian Mountains Limited cleared its position and left the market.

According to the data, Shanghai Aohua Endoscopy Co., Ltd. was established in 1994 and listed on the Science and Technology Innovation Board in 2021, mainly engaged in the research and development, production and sales of electronic endoscopic equipment, including 4K ultra-high-definition endoscopic systems, optical magnifying endoscopes, digestive endoscopes, nasopharyngoscopes and bronchoscopes.

In terms of performance, on January 22, Aohua Endoscopy announced that the company expects to achieve revenue of 731 million yuan to 754 million yuan in 2024, an increase of 7.73%-11.25% year-on-year; It is estimated that the net profit attributable to the parent company will be 15.73 million yuan - 23.38 million yuan, a year-on-year decrease of 59.59% - 72.81%. It is worth noting that Aohua Endoscopy expects to deduct non-net profit of -12.74 million yuan to -5.09 million yuan in 2024, the first loss since listing.

Aohua Endoscopy explained that during the reporting period, the company's overseas business income increased to a certain extent compared with last year, driving the overall revenue growth. At the same time, the company's domestic business revenue growth was limited due to the decline in the total amount of bidding and bidding. In addition, the company's sales expenses, management expenses, and R&D expenses all showed a growth trend, and the growth rate was greater than the company's revenue growth rate.

Aohua Endoscopy also revealed that during the reporting period, the company is expected to be unable to complete the company-level performance appraisal set in part of the assessment period of the "2022 Restricted Stock Incentive Plan" and "2023 Restricted Stock Incentive Plan", and reverse the cumulative share-based payment expenses recognized in the previous year in 2024.

In the secondary market, as of the close of trading on the 7th, Aohua Endoscopy fell 2.30% to 40.69 yuan per share, with a total market value of 5.476 billion yuan.